Using the BLISS-LN phase 3 study of belimumab, investigators studied biomarker associations with kidney response in lupus nephritis.

Belimumab demonstrates notable efficacy for enhancing treatment outcomes among adults with active systemic lupus erythematosus when added to standard therapy. Belimumab demonstrates notable efficacy ...

In pediatric patients with frequently relapsing nephrotic syndrome (FRNS), the therapy was well tolerated, but did not lead to significant changes in disease course. A new report suggests that despite ...

Please provide your email address to receive an email when new articles are posted on . Children treated with belimumab were more likely to achieve primary efficacy renal response vs. standard ...

Please provide your email address to receive an email when new articles are posted on . A 2-year randomized controlled trial has found that belimumab plus standard therapy is superior to standard ...

The European Medicines Agency (EMA) has recommended approval of a self-injectable form of belimumab (Benlysta, GlaxoSmithKline) as an add-on therapy for adults with the most common form of lupus, ...

Adding a single cycle of rituximab to belimumab (Benlysta) did not improve disease control for patients with systemic lupus erythematosus (SLE) in comparison with belimumab alone in a phase 3 ...

Belimumab is a monoclonal antibody, prescribed for active, autoantibody-positive, systemic lupus erythematosus (SLE) who are receiving standard therapy. The therapeutic efficacy of Bacillus ...

systemic sclerosis systemic lupus erythematosus pulmonary arterial hypertension Belimumab is a B-lymphocyte stimulator-specific inhibitor. The Food and Drug Administration (FDA) has granted Orphan ...

In older adults (ages 65+) with lupus, belimumab (Benlysta®) is a safe and effective treatment option, and is beneficial in overall populations with the disease. Belimumab was the first FDA-approved ...